Novartis: Presents Leukemia Study at ASCO


(CercleFinance.com) – Novartis’ Scemblix® shows superior long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia study.

Novartis presented longer-term follow-up data from the Phase III ASCEMBL study for patients with chronic myeloid leukemia at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Scemblix® (asciminib) continues to show superior efficacy with a more than two-fold improvement in major molecular response rate compared to Bosulif® (bosutinib) at 96 weeks (37.6% vs. 15.8%), in s based on the results obtained at 24 weeks.

‘In chronic cancer where resistance may develop to many of the existing therapies, or where patients may see their quality of life negatively affected by treatment side effects over time, it is encouraging to see sustained and increasing efficacy. with consistent adequate tolerance for patients treated with Scemblix over the long term,” said Jorge E. Cortes, MD, Director, Georgia Cancer Center, Augusta University.

‘These 96-week data show the potential of Scemblix and its unique mechanism of action to help change the treatment paradigm for CML.’

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85